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Abstract
Background: The presence of circulating tumor cells (CTC) in the peripheral blood of cancer patients has been
described for various solid tumors and their clinical relevance has been shown. CTC detection based on the
analysis of epithelial antigens might be hampered by the genetic heterogeneity of the primary tumor and loss of
epithelial antigens. Therefore, we aimed to identify new gene markers for the PCR-based detection of CTC in
female cancer patients.
Methods: Gene expression of 38 cancer cell lines (breast, ovarian, cervical and endometrial) and of 10 peripheral
blood mononuclear cell (PBMC) samples from healthy female donors was measured using microarray technology
(Applied Biosystems). Differentially expressed genes were identified using the maxT test and the 50% one-sided
trimmed maxT-test. Confirmatory RT-qPCR was performed for 380 gene targets using the AB TaqMan® Low Density
Arrays. Then, 93 gene targets were analyzed using the same RT-qPCR platform in tumor tissues of 126 patients with
primary breast, ovarian or endometrial cancer. Finally, blood samples from 26 healthy women and from 125 patients
(primary breast, ovarian, cervical, or endometrial cancer, and advanced breast cancer) were analyzed following
OncoQuick enrichment and RNA pre-amplification. Likewise, hMAM and EpCAM gene expression was analyzed in the
blood of breast and ovarian cancer patients. For each gene, a cut-off threshold value was set at three standard
deviations from the mean expression level of the healthy controls to identify potential markers for CTC detection.
Results: Six genes were over-expressed in blood samples from 81% of patients with advanced and 29% of patients
with primary breast cancer. EpCAM gene expression was detected in 19% and 5% of patients, respectively, whereas
hMAM gene expression was observed in the advanced group (39%) only. Multimarker analysis using the new six
gene panel positively identified 44% of the cervical, 64% of the endometrial and 19% of the ovarian cancer patients.
Conclusions: The panel of six genes was found superior to EpCAM and hMAM for the detection of circulating
tumor cells in the blood of breast cancer, and they may serve as potential markers for CTC derived from
endometrial, cervical, and ovarian cancers.
Background
Worldwide, more than two million women are diag-
nosed with breast, cervical, endometrial or ovarian
cancer each year. These cancers contribute to 45% of
total female malignancies and approximately 880000
cancer related deaths annually [1]. Although several
improvements have been made in early diagnosis during
the past few decades, many patients still die of visceral
metastasis, which is the main cause for tumor-related
death. In these patients, the hematogenous spread of
malignant cells remains undetected at the time of initial
therapy. Since T. R. Ashworth first reported circulating
tumor cells (CTC) in the blood of cancer patients in
1869 [2], the presence of CTC has been described for
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several solid tumors, such as colorectal, lung, kidney,
squamous oesophageal, liver, prostate and pancreatic
cancer [3]. Among cancers specific to women, the
majority of CTC based research has been performed in
breast cancer patients (reviewed in [3-6]), whereas few
data exist for CTC in ovarian [7,8], cervical [9], and
endometrial cancer [10,11] patients. Recent studies have
demonstrated the prognostic role of CTC [12-14]; and
the presence of tumor cells in the peripheral blood was
considered to be established as an additional staging
parameter [15]. Hence, many efforts have been made to
develop reliable procedures for the sensitive and specific
detection of CTC, either at the protein level (antibody-
based cell staining) or at the mRNA level (reverse tran-
scription PCR). While the first approach is the gold
standard technique for the detection of tumor cells in
the bone marrow of breast cancer patients, the latter
has been proven to be more sensitive and amenable to
high-throughput analysis [6]. Nevertheless, the detection
of CTC is often hampered by the heterogeneity of the
primary tumor and by the loss of epithelial antigens as
occurs during epithelial to mesenchymal transition [3].
It has been shown that normal-like breast cancer cells
characterized by aggressive behaviour and worse treat-
ment options are not recognized by the CellSearch cir-
culating tumor cell test (Veridex LLC, San Diego, CA),
which uses EpCAM for cell isolation [16]. This test is
the only diagnostic test that is currently approved by
the US Food and Drug Administration for the auto-
mated detection and enumeration of circulating tumor
cells [17]. EpCAM (epithelial cell adhesion molecule) is
not a perfect marker for CTC detection due to the high
variation in its gene expression between tumor subtypes
and its illegitimate transcription from leukocytes [18],.
Likewise, the analysis of hMAM (human mammaglobin
A), the most widely studied marker after CK19 (cytoker-
atin 19) in breast cancer patients, gene expression iden-
tifies patients with nearly 100% specificity at the same
sensitivity as CK19 (1 tumor cell in 106 peripheral blood
mononuclear cells) [19,20]. Nevertheless, mammaglobin
A gene expression is highly variable in female cancers
and is detected in the blood of approximately 10 to 30%
of breast cancer patients [21]. Hence, there is a high
scientific and clinical need for the identification of new
markers for the detection of CTC.
In this study, we aimed to identify new gene markers
for the RT-qPCR based detection of CTC in the blood of
female cancer patients following a step-down strategy
utilizing a whole genome analysis with oligonucleotide
microarrays (Applied Biosystems) and TaqMan® Low
Density Array (TLDA) based RT-qPCR using microflui-
dic technology. Based on the results of these experiments,
a panel of six candidate gene markers was selected for
future routine diagnosis of circulating tumor cells.
Methods
Experimental plan
A step down strategy as depicted in Figure 1 was fol-
lowed to identify gene markers for the detection of
CTC. In the first step, microarray analysis of tumor cell
Figure 1 Graphical scheme of the experimental plan. Following a step down strategy, six genes from initially 27.686 genes were identified as
new gene markers for the RT-qPCR based detection of circulating tumor cells (CTC). In microarray analysis, we compared expression profiles of
PBMC isolated by Ficoll gradient centrifugation from healthy individuals and various established cancer cell lines. In microarray validation, we
compared expression profiles of PBMC isolated by Oncoquick from healthy individuals and cell lines. cDNA was amplified according to a
published protocol [25]. For the experimental analysis of patients samples, we used Oncoquick only. cDNA was amplified using the
TargetAmp™1-Round aRNA Amplification Kit.
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lines and peripheral blood mononuclear cells (PBMC)
from healthy female donors was performed. Second, the
expression levels of a subset of all differentially
expressed genes and of further known or supposed CTC
markers were verified with RT-qPCR using the AB Taq-
Man® Low Density Array (TLDA) platform. In the third
step, genes with absent or very low expression levels in
healthy PBMC were selected for the analysis of blood
samples taken from patients before initial surgery of the
primary tumor using the same RT-qPCR platform. As
the number of circulating tumor cells was suspected to
be low, a RNA pre-amplification step was performed.
Again, a healthy control group was analysed. The aim of
the third step was to identify new gene markers for the
RT-qPCR based detection of CTC.
Ethical considerations
The study was approved by the Ethics Committee from
the Medical University of Vienna, Austria (reference
numbers 366/2003 and 260/2003) and by the Institu-
tional Review Board of the Charité Hospital. All periph-
eral blood and tumor tissue samples were collected with
the patients’ written consent.
Cell culture
Overall, 10 breast cancer cell lines (MCF-7, T-47 D,
MDA-MB-231, Hs 578T, MDA-MB-435 S, MDA-MB-
453, BT-474, SK-BR-3, ZR-75-1, BT-549), 10 ovarian
cancer cell lines (A2780, Caov-3, ES-2, NIHOVCAR-3,
SK-OV-3, TOV-21G, TOV-112 D, OV-90, OV-MZ-01a,
OV-MZ-6), 9 cervical cancer cell lines (HeLa, SW756,
GH354, Ca Ski, C-4 I, C-33 A, HT-3, ME-180, SiHa),
and 9 endometrial cancer cell lines (KLE, RL95-2, AN3
CA, HEC-1-B, Ishikawa, Colo 684, HEC-50-B, EN, EJ)
were cultivated according to the recommended proto-
cols and harvested on at least three consecutive days. If
commercially available, the cell lines were purchased
from the American Type Culture Collection (ATCC,
http://www.atcc.org) or from the European Collection of
Cell Cultures (ECACC, http://www.ecacc.org.uk).
Peripheral blood and tumor tissues
From 2001 to 2006 peripheral blood (PB) samples were
collected from 567 patients with malign gynecological
diseases at the Department of Obstetrics and Gynecol-
ogy and at the Department of Medicine I, Division of
Oncology (all located at the MUW Medical University
of Vienna, A). Patients with tumors of low malignant
potential (i.e. borderline tumor of the ovaries), with con-
comitant or previous malignant tumors other than from
the breast, the ovaries or the uterus, transplanted
patients, and pregnant patients were excluded. Finally,
we included one blood sample from 94 patients (21
breast, 23 ovarian, and each 25 cervical and endometrial
cancer patients) taken before the initial treatment (exci-
sion of the primary tumor or administration of systemic
neoadjuvant chemotherapy). Additionally, we analyzed
one blood sample from 31 patients with recurrent breast
cancer and distant metastasis.
PB taken from 58 healthy female volunteers at the
MUW Department of Blood Group Serology and Trans-
fusion Medicine, the MUW Department of Obstetrics
and Gynecology and ViennaLab Diagnostics GmbH
(Vienna, A) served as negative controls. All PB samples
were collected in EDTA tubes and processed within
2 hours after venipuncture. The patient characteristics
are given in Table 1.
In the same time period, fresh frozen tissue samples
from patients with breast, ovarian, endometrial or cervi-
cal carcinoma were kindly provided by the MUW
Department of Gynecopathology, Clinical Institute for
Pathology. Additional ovarian cancer tissues were col-
lected by the Department of Obstetrics and Gynecology
at the Charité-Universitätsmedizin Berlin (TOC =
Tumorbank Ovarian cancer) (D). All tissue samples were
stored in liquid nitrogen prior to homogenization. The
study inclusion criteria were the same as for blood sam-
ples; furthermore, recurrent patients and tissue samples
taken after neoadjuvant chemotherapy were excluded.
From a total of about 340 collected tumor tissues 50, 51
and 25 patients with primary breast, ovarian or endome-
trial cancer, respectively were enrolled in the study.
The patient characteristics are summarized in Addi-
tional file 1.
Cell spiking
For sensitivity assays, a defined number of T-47 D
breast cancer cells were added to each 15 ml pre-cooled
PB sample obtained from a healthy female donor and
provided by the Austrian National Red Cross Society.
An unspiked blood sample from the same donor served
as a negative control. Each blood sample was spiked in
duplicate. Samples were enriched by OncoQuick (Grei-
ner Bio-One, Frickenhausen, D) per the manufacturer’s
instructions, resuspended in RLT-buffer (Qiagen RNA
Isolation Kit), and the corresponding lysates pooled to
compensate for varying recovery rates of the enrichment
procedure. 1/6 of the extracted total RNA (Qiagen RNA
Isolation Kit) was pre-amplified in triplicate reactions
employing the TargetAmp™1-Round aRNA Amplifica-
tion Kit (Epicentre, Madison WI, USA) according to
manufacturer instructions. The pre-amplified RNA was
converted into cDNA with M-MLV Reverse Transcrip-
tase, RNase H Minus (Promega, Madison WI, USA) and
random hexamers as primers. To assess the sensitivity
of the TLDA platform to detect circulating tumor cells,
RT-qPCR was performed using the TLDA format 96a as
described below.
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Sample processing
For the microarray-based gene expression studies,
PBMC were isolated from 50 ml healthy female blood
by a density gradient using Ficoll-Paque™Plus (GE
Healthcare Bio-Sciences AB, Uppsala, S) per the
standard procedure. For gene expression analysis with RT-
qPCR, which required an enhanced depletion of leuko-
cytes than is provided by Ficoll, mononuclear cells from
15-25 ml PB taken from healthy females and patients were
enriched using OncoQuick® tubes (Greiner Bio-One,
Frickenhausen, D) according to the manufacturer’s
instructions.
100 mg of fresh frozen tumor tissue was pulverized
for 2 min at 2000 rpm using a microdismembrator (B.
Braun Biotech., Melsungen, D) and further homogenized
in lysis solution by intense vortexing.
RNA extraction
Total RNA was extracted with two commercially avail-
able kits depending on the amount of cells in the start-
ing material: First, the Total RNA Isolation Mini Kit
(Agilent Technologies, Waldbronn, D) was used for
RNA extraction from cultivated tumor cells, from
homogenized tumor tissue and from PBMC enriched
by Ficoll-Paque™Plus density gradient centrifugation.
Total RNA samples were spectrophotometrically quan-
tified and examined for residual genomic DNA by PCR
employing primers which span exon 9 of the breast
cancer 2, early onset gene BRCA2 (sense primer: 5’-
ATA ACT GAA ATC ACC AAA AGT G-3’; antisense
primer: 5’-CTG TAG TTC AAC TAA ACA GAG G-
3’). Residual genomic DNA was digested by DNase I.
Finally, quality assessment of the cell line- and PBMC-
RNA was performed with the RNA 6000 Nano LabChip
Kit run on the 2100 Bioanalyzer (Agilent Technologies,
Waldbronn, D) and of RNA samples isolated from
Table 1 Base line characteristics of patients included into
the RT-qPCR analysis of peripheral blood
Venipuncture
A B
Total number of patients 94 31
Breast cancer
Number 21 31
Age (yrs)
median 54 50
range 35-78 25-75
Histology
IDC 100.0% 64.5%
ILC 0 12.9%
Others/unknown 0 22.6%
TNM Stage *
I 38.1% 3.2%
II 33.3% 48.4%
III 23.8% 19.4%
IV 4.8% 3.2%
Unknown 0 22.6%
Endometrial cancer
Number 25 0
Age (yrs)
median 64
range 30-83
Histology
Endometrioid 100.0%
FIGO Stage
I 60.0%
II 8.0%
III 28.0%
IV 4.0%
Cervical Cancer
Number 25 0
Age (yrs)
median 48
range 29-78
Histology
Non-keratinizing 48.0%
Keratinizing 40.0%
Others/unknown 12.0%
FIGO Stage
I 8.0%
II 44.0%
III 28.0%
IV 20.0%
Ovarian cancer
Number 23 0
Age (yrs)
Table 1 Base line characteristics of patients included into
the RT-qPCR analysis of peripheral blood (Continued)
median 53
range 37-78
Histology
Serous 72.7%
Mucinous 12.1%
Others/unknown 15.1%
FIGO Stage
I 10.0%
II 10.0%
III 65.0%
IV 15.0%
Peripheral blood was taken from 94 patients before initial treatment of the
primary tumor (A). From 31 recurrent breast cancer patients (B) the blood was
taken during disease progression (* TNM stage refers to the primary tumor).
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tumor tissues with denaturing agarose gel electrophor-
esis. The total RNAs extracted from at least three conse-
cutive cell line harvests were combined to compensate
for differences in expression that may result from vary-
ing culture conditions. Each of the RNA pools and the
RNA samples extracted from healthy PBMC were preci-
pitated to reach a minimal final concentration of 1.5 μg/
μl. Second, the RNeasy Micro Kit (Qiagen, Hilden, D)
was used for RNA extraction from cells enriched by
Oncoquick® gradient. Because we expected low RNA
yields, we restrained from losing further material by
assessing the RNA quality or quantity in these samples.
Expression profiling using Human Genome Microarrays
A total of 48 Human Genome Survey Microarrays Hs.v1
(Applied Biosystems, Foster City CA, USA) were per-
formed to compare the gene expression of 38 tumor cell
lines and 10 healthy control samples at GeneSys Labora-
tories GmbH (Muenster, D) under standard conditions
using kits, reagents and the chemiluminescent microar-
ray analyzer 1700 from AB. In brief, 20 μg of total RNA
was used to prepare digoxigenin-labeled cDNA, which
developed a chemiluminescent signal after hybridizing
to the 60-mer oligonucleotide probes spotted onto the
microarray platform. Primary analysis and quality con-
trol were performed using the AB Navigator Software
Version 1.0.0.3. After background correction, data were
normalized using the ABI 1700 Chemiluminescent Ana-
lyzer first by feature, then by spatial effects in the slide.
Finally a global normalization per slide was performed.
AB provides the normalized data in the column assay
normalized signal (ANS). The log base 2 ANS was con-
sidered for further analysis. Microarray expression mea-
surements with a flag of greater than 5000 indicating a
low quality spot were filtered out. These measurements
generally correlate with spots that have a signal to noise
ratio smaller than or equal to 3. Since we are interested
in genes that are not expressed in healthy controls, only
those gene probes with an average ANS in the control
samples that was smaller than 1.5 were subjected to sta-
tistical analysis. We performed two statistical tests in
parallel to identify differentially expressed genes. For the
maxT test from the multtest Bioconductor package [22],
genes were considered differentially expressed if they
contained a corrected p-value ≤ 0.05 [23] Additionally
we used a 50% one-sided trimmed maxT-test [24] with
a familywise error rate of 0.05 and 1000 permutations.
This test resembles the ordinary maxT test but replaces
the t-statistic with a trimmed t-statistic in both the ori-
ginal and the permuted data. For each gene of the origi-
nal and each permuted data set, the trimmed t-statistic
is computed from only those data values, which are
greater than the group medians. In contrast to the
maxT test, the 50% one-sided trimmed maxT-test can
identify genes, which are over-expressed in only a sub-
group of the tumor cell lines.
Finally, 356 genes with a mean difference between
tumor cell lines compared to the healthy control sam-
ples of greater than 10 were selected for confirmatory
gene expression profiling by RT-qPCR using the AB
TaqMan® Low Density Array (TLDA) platform. Addi-
tionally, the selected 356 genes were supplemented with
15 known or supposed markers for CTC detection.
Verification of microarray results with RT-qPCR
The expression levels of the 356 genes selected from the
microarray analyses and of the 15 known or supposed
CTC markers were verified with RT-qPCR in a subset
of each five breast, ovarian and endometrial cancer cell
lines and in blood samples from 19 healthy females. RT-
qPCR was performed on the AB 7900HT Fast Real-time
PCR System per manufacturer instructions using the
TLDA format 384 for the analysis of 380 gene targets in
single reactions and of one mandatory endogenous con-
trol gene (glyceraldehyde-3-phosphate dehydrogenase
[GAPDH]) in a quadruplicate reaction. The 380 gene
targets consisted of the 3 additional TaqMan® Endogen-
ous Controls (beta-2-microglobulin [B2M], TAT-box
binding protein [TBP], and phosphoglyceratekinase 1
[PGK]) and 377 TaqMan® Gene Expression Assays spe-
cific for the 15 known or supposed CTC marker and
specific for the previously selected differentially
expressed genes according to a mapping of microarray
probe IDs to assay IDs provided by AB. The RNA
extracted from tumor cell lines was converted into
cDNA with M-MLV Reverse Transcriptase, RNase H
Minus (Promega, Madison WI, USA) and random hex-
amers as primers. Blood mononuclear cells were
enriched with Oncoquick density gradient centrifuga-
tion. Then, the extracted RNA was amplified following a
modified version of a protocol published by Klein et al.
[25]. In short, the RNA was first converted into cDNA
with M-MLV Reverse Transcriptase, RNase H Minus
(Promega, Madison WI, USA) and random primers con-
taining a 5’-oligo-dC flanking region (5’-[CCC]5 TGC
AGG N6-3’; VBC Genomics, Vienna, A). After generat-
ing a 3’-oligo-dG flanking region, the flanked cDNA was
primed with CP2 (5’-TCA GAA TTC ATG [CCC]5-3’;
VBC Genomics) and amplified with Super Taq (HT Bio-
technology Ltd., Cambridge, GB). The TLDA were
loaded with the sample-specific PCR mix containing the
template cDNA as recommended by the manufacturer
(2 ng per well). Raw data were analyzed with the AB
7900 Sequence Detection Software version 2.2.2 using
automatic baseline correction and a manual cycle
threshold (Ct) setting. Resulting Ct data was exported
for further analysis. To downsize the number of poten-
tial candidate genes from initially more than 27.000
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genes to about 100 genes, all genes with expression
levels beyond the RT-qPCR detection limit (i.e. Ct 50) in
the healthy control samples were excluded. The remain-
ing genes were sorted in descending order by their aver-
age Ct value obtained from the 15 tumor cell lines. The
first 93 genes were selected for RT-qPCR analysis of
blood and tissue samples taken from tumor patients
using the TLDA 96a format. Additionally, three genes
(B2M, GAPDH and PGK) were selected as internal
reference genes.
Gene expression analysis of tumor tissue samples
The expression of the previously selected 93 genes was
measured in tumor tissue samples from patients with
primary breast (N = 50), ovarian (N = 51) and endome-
trial cancer (N = 25) with RT-qPCR using the TLDA
96a format to verify their use as candidate markers for
the detection of CTC in the blood of cancer patients.
RNA was converted into cDNA by Omniscript Reverse
Transcriptase (Quiagen, Hilden, D) using an oligo-
dT-flanked primer. Loading the microfluidic cards,
RT-qPCR amplification, and raw data analysis were per-
formed as described in the last preceding section. All
samples were analyzed in duplicates.
Gene expression analysis of patients’ blood samples
The expression of the same 93 genes was evaluated in
blood samples from healthy female volunteers (N = 26)
and in peripheral blood samples from patients with
breast (N = 52), ovarian (N = 23), cervical and endome-
trial cancer (25 patients each), using the TLDA 96a RT-
qPCR platform. After cell enrichment with OncoQuick
density gradient centrifugation 1/6 of the total RNA was
amplified employing the TargetAmp™1-Round aRNA
Amplification Kit (Epicentre, Madison WI, USA) per
manufacturer instructions. The amplified RNA was con-
verted into cDNA with M-MLV Reverse Transcriptase,
RNase H Minus (Promega, Madison WI, USA) and ran-
dom hexamers as primers. Loading of the microfluidic
cards, RT-qPCR amplification, and raw data analysis
were performed as described in the microarray verifica-
tion section. All samples were analyzed in duplicate.
The mean of the resulting duplicate Ct values was used
as a quantitative value. If only one of the duplicates was
positive (i.e. Ct < 50), the positive Ct value was taken.
Low-level expression of many genes in the peripheral
blood of the healthy control group decreased the overall
specificity of the assay and required the introduction of
a cut-off threshold value to separate the cancer patient
group from the healthy control group:
As proposed by Mikhitarian et al. [26], a threshold
value TX for each gene X was set to three standard
deviations from the mean dCtX value in the control
group. dCtX values were calculated by normalizing the
average expression of gene X to the average expression
of the endogenous control gene GAPDH. If only one
healthy control sample revealed detectable gene expres-
sion, the one dCtX was taken as cut-off threshold value.
A tumor patient was considered positive for the molecu-
lar analysis of gene × if dCtX was below the defined
threshold value TX.
Additionally, hMAM- and EpCAM-specific RT-qPCR
was performed for the same set of breast and ovarian
cancer blood samples and for healthy female control
samples after cell enrichment and RNA pre-amplifica-
tion as described above using individual AB TaqMan®
Pre-Developed Assay Reagents (Hs00267190_m1 and
Hs00158980_m1).
Results
RNA quality assessment
Prior to microarray hybridization and RT-qPCR analysis,
the RNA extracted from the tumor cell lines and the
healthy PBMC was checked for quality with the RNA
6000 Nano LabChip Kit run on the Agilent 2100 Bioa-
nalyzer. As a result, 85% of the RNA samples were of
very good RNA quality (RIN≥8), 60% of which were
considered to have an excellent quality (RIN≥9).
Differentially expressed genes in tumor cell lines
compared to healthy PBMC
We compared the gene expression profile of 38 estab-
lished cancer cell lines to those of PBMC taken from 10
healthy donors to identify genes that were not expressed
or expressed at very low level in the peripheral blood of
healthy females but appeared very highly expressed in
the cancer cell lines. From the 18151 (54.8%) genes with
an average ANS < 1.5 in the healthy control samples
maxT-test identified 457, 534, 526, and 503 genes differ-
entially expressed for the breast, cervical, endometrial,
and ovarian cancer cell lines, respectively. These genes
comprised 54, 81, 63, and 60 genes with cancer-type
specific expression for the respective cancer cell lines.
Additionally, the 50% one-sided trimmed maxT-test
identified further 25, 27, 20 and 29 genes, which were
differentially expressed in the breast, cervical, endome-
trial and ovarian cancer cell lines compared to the
healthy controls.
Finally, 356 differentially expressed genes were chosen
for confirmatory gene expression profiling with RT-
qPCR using the TLDA 384 format (microarray data are
provided in Additional file 2). This consisted of 337
genes identified by the maxT-test, 19 by the 50% one-
sided trimmed maxT-test only, and the 4 genes:
EFEMP1, EPS8L1, CRYZL1 and PCDHG represented
with more than one TaqMan® Assay. Additionally we
decided to analyze nine markers of well-known tumor
specificity (ERBB2, ESR1, PGR, PLAT, SCGB2A1,
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SCGB2A2, SERPINE1, SERPINE2 and TFF1) and six
candidate markers for CTC detection that were pre-
viously identified by our research group (COL3A1, GHR,
CALB1, LPHN1, FN1 and EDNRA) [27].
Verification of microarray results with RT-qPCR
146 genes of the TLDA 384 gene set were identified as
potential markers for the detection of CTC in the blood
of cancer patients with expression levels below the detec-
tion limit of RT-qPCR (i.e. Ct 50) in the healthy control
group. The genes were sorted in descending order by
their average Ct value obtained from the 15 tumor cell
lines, and the first 93 genes were selected for further
gene expression analysis of patients’ samples using the
TLDA 96a format (see Additional file 3). None of the 15
known or supposed markers for CTC detection was con-
sidered for further investigations either due to detectable
expression levels (ERBB2, ESR1, SERPINE1, SERPINE2
and FN1) in healthy controls or due to inadequate gene
expression in the tumor cell lines.
Sensitivity
To assess the applicability of the TLDA platform for the
RT-qPCR based detection of circulating tumor cells, the
expression levels of the specified 93 genes were mea-
sured in healthy female blood samples spiked with T-47
D breast cancer cells. CCNE2 and MAL2 transcripts
were detected in blood samples spiked with at least 26
and 3 tumor cells per ml blood, respectively (Figure 2),
but they were not detected in the unspiked blood.
Although background expression of EMP2, PPIC,
DKFZp762E1312, and SLC6A8 was detected in the
unspiked blood, increasing expression levels of the
respective genes were observed when tumor cells had
been added to the blood, with a detection limit of 3
(EMP2, PPIC) and 26 tumor cells per ml of blood
(DKFZp762E1312, SLC6A8). Furthermore, the spiking
experiments revealed that RT-qPCR might be less sensi-
tive using the TLDA platform than using conventional
PCR tubes, because linear amplification patterns distin-
guishing each 10-fold dilution were only observed with
Ct values smaller than 35 (data not shown).
Gene expression in tumor tissues
The gene expression of the previously selected 93 genes
was confirmed in tumor samples from patients with pri-
mary breast, ovarian and endometrial cancer. We
observed that the house-keeping gene expression levels
were lower in ovarian cancer tissues than in tumor tis-
sues of breast and endometrial cancer patients (GAPDH
24.2 ± 2.6, 22.2 ± 1.2, 22.7 ± 1.4 (SD) Ct; B2 M 22.1 ±
3.4, 18.1 ± 1.5, 17.7 ± 1.9 (SD) Ct; PGK 25.5 ± 2.7, 23.5
± 1.1, 22.4 ± 3.0 (SD) Ct in the respective tumor
patients). Two of the 93 genes were found to be tumor-
site specific: PLEKHC1 (pleckstrin homology domain
containing, family C [with FERM domain] member 1)
and SGCB (sarcoglycan beta) transcripts were detected
only in ovarian cancer patients (see Additional file 4),
although they were also detected in cancer cell lines of
breast and endometrial origin either. Interestingly,
Figure 2 Sensitivity of RT-qPCR using TLDA platform. Expression levels of 93 candidate genes were analyzed using cDNA generated from
total RNA isolated from peripheral blood samples from a healthy female donor and the same blood spiked with 4, 40 and 400 T47-D tumor
cells after cell enrichment. RNA was pre-amplified using the TargetAmp™1-Round aRNA Amplification Kit. Average Ct values obtained from RT-
qPCR amplification of CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, and SLC6A8 transcripts using the TLDA format are shown. MAL2 and CCNE2 gene
expression was below the detection limit of RT-qPCR in the unspiked blood. The detection sensitivity of the respective marker gene was
estimated to be 40 and 400 tumor cells per 15 ml whole blood.
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expression of the selected 93 genes was detected in
more ovarian cancer patients than in breast and endo-
metrial cancer patients (median percentage of positive
patients in the respective tumor groups was 78.4%,
64.0% and 32.0%).
Gene markers for CTC detection
The expression of the previously selected 93 genes was
evaluated in blood samples from cancer patients, to iden-
tify the most promising markers for CTC detection. At
primary diagnosis, each 17 (68.0%) cervical and endome-
trial cancer, 6 (26.1%) ovarian cancer and 8 (38.1%)
breast cancer patients over-expressed at least one out of
the 93 potential candidate genes at levels above the
defined threshold. At the time-point of disease recur-
rence, 27 (87.1%) breast cancer patients were positive for
at least one gene. Of the 93 candidate genes, 40 were able
to identify patients using the defined respective thresh-
olds. 33 of these genes were capable to identify patients
with primary breast cancer, and this number was reduced
to 15 for patients with advanced disease stage. 14 of these
genes could identify patients with cervical and endome-
trial cancer and four of the 40 genes identified ovarian
cancer patients. The remaining 55 genes did not provide
any value due to similar expression levels in both the
healthy control and cancer patient groups.
The purpose of this study was to identify a panel of
genes for future multi-marker RT-qPCR based analysis
to increase the sensitivity to detect circulating tumor
cells. For this purpose, we selected those genes, which
were over-expressed in more than 10% of the patients
with recurrent breast cancer, since circulating tumor
cells are more likely in advanced disease. According to
this criterion, six genes (CCNE2, DKFZp762E1312,
EMP2, MAL2, PPIC and SLC6A8) were chosen for a
RT-qPCR marker panel. Using this panel 81% of the
breast cancer patients with recurrence and 29% of the
breast cancer patients at initial diagnosis were positive
for at least one gene. In the cervical, endometrial and
ovarian cancer groups, the percentage of positive
patients was found to be 44%, 64% and 19%, respectively
(see Table 2 and Figure 3).
Additionally, hMAM-specific RT-qPCR performed for
the same set of breast and ovarian cancer blood samples
confirmed the tissue specific expression of mammaglo-
bin A. Transcripts were only detected in recurrent
breast cancer patients with an incidence of 38.7%, but
neither in primary breast cancer patients, ovarian cancer
patients, nor in the healthy controls. Likewise, EpCAM
gene over-expression was detected in the blood of
neither ovarian cancer patients nor healthy females. In
the blood of breast cancer patients, we found EpCAM
over-expression in 5.0% of the patients at primary diag-
nosis and in 19.4% of the patients with clinical evidence
of disease recurrence (see Table 2).
Discussion
Using a stepwise approach combining genome-wide
expression profiling and TaqMan® based RT-qPCR we
identified six genes (CCNE2, DKFZp762E1312, EMP2,
MAL2, PPIC, and SLC6A8) as potential markers for the
detection of circulating tumor cells in the peripheral
blood of patients with breast cancer and gynecological
malignancies. Although each of these genes is implicated
in cancer, they have not previously been specified for
the detection of circulating tumor cells in cancer
patients.
Initial screening of candidate gene markers for CTC
detection was performed using a microarray-based gene
expression analysis of human cancer cell lines and
mononuclear blood cells obtained from healthy females.
After verification of the microarray results, a set of 93
gene markers was selected for the RT-qPCR analysis of
blood samples from healthy females and from patients
with breast, ovarian, endometrial, and cervical cancer.
Due to background gene expression in the healthy
blood samples, a rigorous cut-off threshold value was
introduced to separate the patients from the healthy
Table 2 Marker gene expression in peripheral blood
Positive blood samples (%)
Patients Panel CCNE2 MAL2 EMP2 SLC6A8 DKFZ PPIC hMAM EpCAM
rec. BC (N = 31) 80.6 32.3 19.4 32.3 45.2 25.8 19.4 38.7 19.4
BC (N = 21) 28.6 23.8 0 4.8 0 4.8 0 0 5.0
OC (N = 23) 19.0 13.0 4.3 0 0 0 0 0 0
EC (N = 25) 64.0 36.0 20.0 12.0 12.0 8.0 8.0 0 0
CC (N = 25) 44.0 40.0 4.0 4.0 4.0 4.0 0 0 0
Healthy (N = 26) 0 0 0 0 0 0 0 0 0
The percentage of patients with RT-qPCR positive blood samples is shown. RT-qPCR positivity was defined as gene expression beyond the cut-off threshold,
which was set for each gene marker at three standard deviations from the mean expression in healthy control blood samples. Positivity in percentage shown for
the “panel” (CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC and SLC6A8) is defined as positivity for at least one of the markers.
(BC: breast cancer, rec. BC: recurrent breast cancer, OC: ovarian cancer, EC: endometrial cancer, CC: cervical cancer, ND: not done)
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controls. We assumed that the over-expression of at
least one gene marker in relation to the defined thresh-
old value indicated the presence of circulating tumor
cells. As patients with recurrent breast cancer are most
likely to harbor circulating tumor cells in their blood,
their blood samples were chosen to identify new gene
markers for CTC detection. A panel of six genes:
CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, and
SLC6A8 that were over-expressed in the blood of 81%
of patients with recurrent breast cancer was then chosen
A 
B 
C 
D 
E 
Figure 3 RT-qPCR analysis of marker gene expression in peripheral blood. Gene expression was analyzed in blood samples taken from
patients (triangles) with recurrent breast cancer (A), and in blood samples taken at first diagnosis from breast (B), endometrial (C), cervical (D) and
ovarian (E) cancer patients. Blood from healthy females (circles) served as a control group. Mononuclear cells were enriched with the Oncoquick
density gradient. RT-qPCR was performed following a RNA pre-amplification step. Average Ct values obtained from duplicates were normalized to
GAPDH gene expression. Cut-off threshold values calculated from the mean average normalized gene expression in healthy female blood as
indicated by horizontal lines for the respective gene markers (DKFZp762E1312 1.39, SLC6A8 2.92, PPIC 3.61, EMP2 6.84, MAL2 14.61, CCNE2 16.83).
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as gene markers for the molecular detection of CTC. In
contrast, at initial diagnosis using the six gene panel
only 29% of the breast cancer patients were RT-qPCR
positive. In addition, the new gene panel identified
patients with other female cancers (i.e. cervical, endome-
trial and ovarian cancer).
In tumor cell spiking experiments the sensitivity of the
applied RT-qPCR was estimated to be 3 to 26 tumor cells
per ml whole blood; similar sensitivities are reported for
RT-qPCR- and immuno-mediated detection (reviewed by
Gervasoni et al. [28]). However, we found out that Taq-
Man® Low Density Arrays are typically not the method of
choice for the detection of rare template molecules.
In the present study, all blood samples were taken
before removal of the tumor masses. To estimate
whether the six gene panel is useful to detect minimal
residual disease, further experiments should include
blood samples from cancer patients taken after the exci-
sion of the primary tumor. Although we have already
analysed several blood samples taken from breast cancer
patients with no evidence of disease six months after
completion of their adjuvant chemotherapy, the follow-
up time is yet too short to make any conclusions con-
cerning the patient outcome.
There are further limitations that need to be acknowl-
edged and addressed regarding the experimental design
of the present study. First, when we evaluated various
approaches for the enrichment of circulating tumor cells
in in the course of the project, we found out that Onco-
quick may insufficiently recover spiked tumor cells, in
particular when only a few tumor cells were added to
the blood (i.e. ≤ 20 tumor cells per 15 ml blood) [29].
For this reason, false-negative RT-qPCR results are likely
to occur for cancer patients with low CTC counts. Sec-
ond, the density of the tumor cells depends on their dif-
ferentiation state. Therefore, undifferentiated tumor
cells having a higher density might pass through the
Oncoquick density gradient. Finally, we cannot exclude
false-positive cases due to non-malignant epithelial cells,
which may contaminate the blood samples during veni-
puncture and which express the targeted transcripts.
Nevertheless, we decided in favour of the Oncoquick
density gradient, because it dramatically reduced back-
ground gene expression of the selected targets in healthy
PBMC samples. To enhance the sensitivity and specifi-
city of the approach, future experiments should primar-
ily aim at improving the recovery rate of the tumour
cell enrichment. Further evaluation of the six CTC mar-
kers should be done without RNA pre-amplification and
using the conventional PCR tube format instead of Taq-
Man® Low Density Array format.
Despite these limitations, we suggest that the RT-
qPCR based analysis of CCNE2, DKFZp762E1312,
EMP2, MAL2, PPIC, and SLC6A8 gene expression in the
blood of patients with breast cancer or gynecologic
malignancies is useful for the detection of circulating
tumor cells, alone or combined with other markers
such as hMAM or EpCAM. Interestingly, the
DKFZp762E1312, EMP2, PPIC, and SLC6A8 transcripts,
but not CCNE2 and MAL2 transcripts were detected in
the blood of healthy females. Therefore, we suppose that
the detection of CCNE2 and MAL2 transcripts in the
blood of cancer patients is indicative for CTC presence
(which had not been verified by immunocytochemistry).
However, the observed increase of CCNE2 mRNA levels
in the diseased group compared to the healthy control
group, which are reported to be undetectable in normal
quiescent cells arrested in G0 [30], is in conflict with the
supposed non-proliferative nature of circulating tumor
cells [31]. Interestingly, both CCNE2 and MAL2 are
located on chromosome 8q, a region which is frequently
increased in copy number in breast [32] and other can-
cer types [32,33], and one of the most important target
genes affected by gains and amplifications of 8q is the
MYC oncogene.
The frequency of hMAM gene expression in the blood
of breast cancer patients is in line with the frequencies
reported by Roncella et al. [20]. 10 of the 12 hMAM
positive blood samples (83%) were also positive when
analyzed using the six gene panel, and 52% of the recur-
rent breast cancer blood samples were solely identified
by CCNE2, DKFZp762E1312, EMP2, MAL2, PPIC, or
SLC6A8. Similarly, the six gene panel identified all of
the EpCAM positive blood samples.
Conclusions
In this study, we identified new gene markers for the
assessment of circulating tumor cells. We have shown
that the RT-qPCR-based multi-marker analysis using
the six genes: CCNE2, DKFZp762E1312, EMP2, MAL2,
PPIC, or SLC6A8 more than doubled the number of
positive patients with recurrent breast cancer compared
to the analysis of hMAM or EpCAM gene expression
alone. Therefore, we suggest that the significantly higher
expression of these six genes in the peripheral blood
indicates the presence of circulating tumor cells. This
multi marker analysis may provide a tool for clinical
monitoring and treatment control of breast cancer and
of gynecological malignancies. Eventually it may also be
useful for the early detection.
Additional material
Additional file 1: Base line characteristics of patients included into
the RT-qPCR analysis of tumor tissue.
Additional file 2: Microarray data of 356 differentially expressed
genes.
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Additional file 3: Gene identifiers of the TLDA 96a platform. 93
genes were selected as CTC candidate genes for the RT-qPCR analysis of
blood and tumor tissue samples from cancer patients. Additionally, three
house-keeping genes (B2M, GAPDH, and PGK1) were chosen as an
internal reference.
Additional file 4: Gene expression in tumor tissues. The percentage
of breast, endometrial and ovarian cancer patients with gene expression
detected by RT-qPCR is shown for each of the 93 candidate genes and
for the three internal reference genes (B2M, GAPDH, and PGK1).
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